Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Excessive Sensitivity to Uncertain Visual Input in L-DOPA-Induced Dyskinesias in Parkinson's Disease: Further Implications for Cerebellar Involvement.

Stevenson JK, Lee C, Lee BS, Talebifard P, Ty E, Aseeva K, Oishi MM, McKeown MJ.

Front Neurol. 2014 Feb 4;5:8. doi: 10.3389/fneur.2014.00008. eCollection 2014.

2.

Dyskinetic Parkinson's disease patients demonstrate motor abnormalities off medication.

Stevenson JK, Talebifard P, Ty E, Oishi MM, McKeown MJ.

Exp Brain Res. 2011 Oct;214(3):471-9. doi: 10.1007/s00221-011-2845-2. Epub 2011 Aug 30.

PMID:
21877102
3.

Response to sensory uncertainty in Parkinson's disease: a marker of cerebellar dysfunction?

Stevenson JK, Oishi MM, Farajian S, Cretu E, Ty E, McKeown MJ.

Eur J Neurosci. 2011 Jan;33(2):298-305. doi: 10.1111/j.1460-9568.2010.07501.x. Epub 2010 Dec 14.

PMID:
21155903
4.

L-dopa induces under-damped visually guided motor responses in Parkinson's disease.

Au WL, Lei N, Oishi MM, McKeown MJ.

Exp Brain Res. 2010 May;202(3):553-9. doi: 10.1007/s00221-010-2156-z. Epub 2010 Feb 9.

PMID:
20143051
5.

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.

Bézard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.

Neurosci Res. 2013 Dec;77(4):242-6. doi: 10.1016/j.neures.2013.10.002. Epub 2013 Oct 14.

PMID:
24135129
6.

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.

Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H.

Brain. 2015 Apr;138(Pt 4):963-73. doi: 10.1093/brain/awu409. Epub 2015 Feb 10.

7.

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.

Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F; Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators.

Mov Disord. 2013 Jul;28(8):1064-71. doi: 10.1002/mds.25364. Epub 2013 Apr 29.

PMID:
23630119
8.

Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.

Pinna A, Ko WK, Costa G, Tronci E, Fidalgo C, Simola N, Li Q, Tabrizi MA, Bezard E, Carta M, Morelli M.

Mov Disord. 2016 Apr;31(4):501-11. doi: 10.1002/mds.26475. Epub 2016 Feb 12.

PMID:
26871939
9.

Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.

Morin N, Morissette M, Grégoire L, Rajput A, Rajput AH, Di Paolo T.

Neuropharmacology. 2015 Dec;99:356-68. doi: 10.1016/j.neuropharm.2015.08.002. Epub 2015 Aug 6.

PMID:
26254863
10.

Increased response to visual feedback of drug-induced dyskinetic movements in advanced Parkinson's disease.

Liu X, Osterbauer R, Aziz TZ, Miall RC, Stein JF.

Neurosci Lett. 2001 May 18;304(1-2):25-8.

PMID:
11335046
11.

Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.

Tronci E, Fidalgo C, Zianni E, Collu M, Stancampiano R, Morelli M, Gardoni F, Carta M.

Neuroscience. 2014 Apr 18;265:245-52. doi: 10.1016/j.neuroscience.2014.01.042. Epub 2014 Jan 30.

PMID:
24486947
12.

Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.

Smith LM, Parr-Brownlie LC, Duncan EJ, Black MA, Gemmell NJ, Dearden PK, Reynolds JN.

Neuroscience. 2016 Jun 2;324:238-51. doi: 10.1016/j.neuroscience.2016.03.012. Epub 2016 Mar 8.

PMID:
26968766
13.

Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.

González-Aparicio R, Moratalla R.

Neurobiol Dis. 2014 Feb;62:416-25. doi: 10.1016/j.nbd.2013.10.008. Epub 2013 Oct 17.

PMID:
24140894
14.
15.

5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.

Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, Devoto P, Carta M.

Neurobiol Dis. 2013 Dec;60:108-14. doi: 10.1016/j.nbd.2013.08.014. Epub 2013 Sep 1.

PMID:
24004632
16.

Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.

Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):446-54. doi: 10.1016/j.pnpbp.2009.12.011. Epub 2009 Dec 16.

PMID:
20026151
18.

Visuomotor adaptation in Parkinson's disease: effects of perturbation type and medication state.

Semrau JA, Perlmutter JS, Thoroughman KA.

J Neurophysiol. 2014 Jun 15;111(12):2675-87. doi: 10.1152/jn.00095.2013. Epub 2014 Apr 2.

19.

[Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].

Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, Matsunaga M.

No To Shinkei. 2002 Feb;54(2):133-7. Japanese.

PMID:
11889759
20.

The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease.

Lemieux S, Ghassemi M, Jog M, Edwards R, Duval C.

Exp Brain Res. 2007 Jan;176(3):465-75. Epub 2006 Aug 30.

PMID:
16944114

Supplemental Content

Support Center